Diabetic cardiomyopathy and metabolic remodeling of the heart

Pavan K. Battiprolu, Camila Lopez-Crisosto, Zhao V. Wang, Andriy Nemchenko, Sergio Lavandero, Joseph A. Hill

Producción científicarevisión exhaustiva

77 Citas (Scopus)

Resumen

The incidence and prevalence of diabetes mellitus are both increasing rapidly in societies around the globe. The majority of patients with diabetes succumb ultimately to heart disease, much of which stems from atherosclerotic disease and hypertension. However, the diabetic milieu is itself intrinsically noxious to the heart, and cardiomyopathy can develop independent of elevated blood pressure or coronary artery disease. This process, termed diabetic cardiomyopathy, is characterized by significant changes in the physiology, structure, and mechanical function of the heart. Presently, therapy for patients with diabetes focuses largely on glucose control, and attention to the heart commences with the onset of symptoms. When the latter develops, standard therapy for heart failure is applied. However, recent studies highlight that specific elements of the pathogenesis of diabetic heart disease are unique, raising the prospect of diabetes-specific therapeutic intervention. Here, we review recently unveiled insights into the pathogenesis of diabetic cardiomyopathy and associated metabolic remodeling with an eye toward identifying novel targets with therapeutic potential.

Idioma originalEnglish
Páginas (desde-hasta)609-615
Número de páginas7
PublicaciónLife Sciences
Volumen92
N.º11
DOI
EstadoPublished - 2013

Financiación

This work was supported by grants from the NIH ( HL-075173 , J.A.H.; HL-080144 , J.A.H.; HL-090842 , J.A.H.), AHA ( 0640084N , J.A.H.; 12POST9030041 , P.K.B.), ADA mentor-based postdoctoral fellowship ( 7-08-MN-21-ADA , J.A.H. and P.K.B.), the AHA-Jon Holden DeHaan Foundation ( 0970518N , J.A.H.), and the Fondo Nacional de Desarrollo Cientifico y Tecnologico : FONDECYT 1120212 and ACT1111 (S.L.). C.L.C. is a recipient of a CONICYT fellowship , Chile.

FinanciadoresNúmero del financiador
AHA-Jon Holden DeHaan Foundation0970518N
National Institutes of HealthHL-075173, HL-080144
National Heart, Lung, and Blood InstituteR01HL090842
American Heart Association12POST9030041, 0640084N
Comisión Nacional de Investigación Científica y Tecnológica
Fondo Nacional de Desarrollo Científico y Tecnológico1120212, ACT1111
Aeronautical Development Agency

    ASJC Scopus Subject Areas

    • General Pharmacology, Toxicology and Pharmaceutics
    • General Biochemistry,Genetics and Molecular Biology

    Huella

    Profundice en los temas de investigación de 'Diabetic cardiomyopathy and metabolic remodeling of the heart'. En conjunto forman una huella única.

    Citar esto